Company Profile
Eli Lilly Stock Price, News & Catalysts
- Ticker:
- LLY
- Exchange:
- NYSE
- Sector:
- Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs
- Location:
- United States
Stock performance
1,157.49 USD (+1.26%)
Close
Last updated: October 6, 2026
949B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, LLY closed up 1.26% at $1157.49. No new same-company headline was identified in the current news window.
Company overview
Global Research-Based Medicines Company
Eli Lilly is a global pharmaceutical company that develops and commercializes medicines using capabilities in biotechnology, medicinal chemistry, and genetic medicine. Its research and commercial portfolio is concentrated in diabetes and obesity, neuroscience, immunology, and oncology, with external acquisitions increasingly adding genetic medicine, infectious disease, and neuropsychiatry programs.
Diabetes and Obesity Leadership
Lilly's largest franchise is built around incretin medicines for metabolic disease. Mounjaro is marketed for type 2 diabetes and Zepbound for chronic weight management and related complications, while oral GLP-1 candidate orforglipron, branded Foundayo in advance of potential commercialization, is intended to broaden access to incretin therapy without injection or food-and-water dosing restrictions. Retatrutide, a once-weekly GIP, GLP-1, and glucagon receptor agonist, is being developed for obesity and complications including obstructive sleep apnea and knee osteoarthritis pain.
Neuroscience and Immunology
The neuroscience portfolio includes Kisunla for early symptomatic Alzheimer's disease and acquired programs addressing sleep-wake disorders and treatment-resistant depression. In immunology, Lilly markets Ebglyss for atopic dermatitis and Omvoh for inflammatory bowel disease, supported by research across chronic inflammatory and autoimmune conditions.
Oncology Portfolio
Lilly's oncology business combines targeted small molecules, biologics, and biomarker-driven development. Commercial products include Jaypirca for B-cell malignancies, Retevmo for RET-driven cancers, and Inluriyo for estrogen receptor-positive breast cancer, while the pipeline includes olomorasib in KRAS G12C-mutated tumors and additional programs added through the acquisition of Ajax Therapeutics.
Genetic Medicine and External Innovation
The company is expanding beyond its traditional discovery platforms through acquisitions and partnerships. Orna Therapeutics and Kelonia Therapeutics add circular RNA and in vivo genetic medicine capabilities, Centessa adds sleep-wake assets, and additional transactions are establishing infectious disease and neuropsychiatry portfolios. VERVE-102, an in vivo PCSK9 base-editing program, illustrates Lilly's interest in potentially one-time genetic treatments for common cardiometabolic disease.
Future catalysts
- U.S. FDA submission of a Biologics License Application for retatrutide in obesity in the first quarter of 2027, supported by the completed Phase 3 registration package covering obesity, obstructive sleep apnea, and knee osteoarthritis pain.
- FDA review and potential decision on the submitted U.S. application for orforglipron in type 2 diabetes.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Eli Lilly (LLY)?
Eli Lilly (LLY) most recently closed at 1,157.49 USD, a +1.26% move versus the previous session.
What is the market cap of Eli Lilly (LLY)?
Eli Lilly currently has a market capitalization of 949B USD on BioPharmSignal.
What does Eli Lilly do?
Global Research-Based Medicines Company Eli Lilly is a global pharmaceutical company that develops and commercializes medicines using capabilities in biotechnology, medicinal chemistry, and genetic medicine. Its research and commercial portfolio is concentrated in diabetes and obesity, neuroscience, immunology, and oncology, with external acquisitions...
On which exchange is LLY stock listed?
Eli Lilly (LLY) is associated with NYSE, United States, Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs.
What is GLP-1?
Mounjaro is marketed for type 2 diabetes and Zepbound for chronic weight management and related complications, while oral GLP-1 candidate orforglipron, branded Foundayo in advance of potential commercialization, is intended to broaden access to incretin therapy without injection or food-and-water dosing restrictions.
Which conditions is Eli Lilly targeting with GLP-1?
Eli Lilly is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Eli Lilly describe recent progress with GLP-1?
U.S. FDA submission of a Biologics License Application for retatrutide in obesity in the first quarter of 2027, supported by the completed Phase 3 registration package covering obesity, obstructive sleep apnea, and knee osteoarthritis pain. FDA review and potential decision on the submitted U.S. application for orforglipron in type 2 diabetes.
What is VERVE-102?
VERVE-102, an in vivo PCSK9 base-editing program, illustrates Lilly's interest in potentially one-time genetic treatments for common cardiometabolic disease.